No connection

Search Results

GELS vs SILO

GELS
Gelteq Limited
BEARISH
Price
$0.77
Market Cap
$8.2M
Sector
Healthcare
AI Confidence
95%
SILO
Silo Pharma, Inc.
BEARISH
Price
$0.52
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
GELS
--
SILO
--
Forward P/E
GELS
--
SILO
-0.74
P/B Ratio
GELS
0.7
SILO
1.09
P/S Ratio
GELS
19.92
SILO
116.19
EV/EBITDA
GELS
-3.15
SILO
-0.1

Profitability

Gross Margin
GELS
72.07%
SILO
38.57%
Operating Margin
GELS
-2969.43%
SILO
-4363.27%
Profit Margin
GELS
0.0%
SILO
0.0%
ROE
GELS
-42.99%
SILO
-74.56%
ROA
GELS
-15.0%
SILO
-35.63%

Growth

Revenue Growth
GELS
59.4%
SILO
0.0%
Earnings Growth
GELS
--
SILO
--

Financial Health

Debt/Equity
GELS
0.27
SILO
--
Current Ratio
GELS
0.27
SILO
11.36
Quick Ratio
GELS
0.14
SILO
10.55

Dividends

Dividend Yield
GELS
--
SILO
--
Payout Ratio
GELS
0.0%
SILO
0.0%

AI Verdict

GELS BEARISH

GELS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. While the company shows strong top-line revenue growth (59.40%) and healthy gross margins (72.07%), these are completely offset by a catastrophic operating margin of -2969.43%. With a current ratio of 0.27 and a quick ratio of 0.14, the company lacks the liquidity to meet its short-term obligations. Despite trading below book value (P/B 0.70), the fundamental instability and long-term price decay make this a high-risk speculative asset.

Strengths
Strong Gross Margin of 72.07%
Robust YoY Revenue Growth of 59.40%
Low Debt-to-Equity ratio (0.27)
Risks
Severe liquidity shortage (Current Ratio 0.27)
Extreme operational inefficiency (Operating Margin -2969.43%)
Weak Piotroski F-Score (3/9) indicating deteriorating fundamentals
SILO BEARISH

SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.

Strengths
Strong short-term liquidity (Current Ratio: 11.36)
Price/Book ratio near 1.09 suggests the stock is trading close to its accounting value
Recent short-term price momentum (+60.9% in 1 month)
Risks
Extreme fundamental weakness (Piotroski F-Score 0/9)
Zero revenue growth (YoY and Q/Q)
Massive operating losses (-4363.27% operating margin)

Compare Another Pair

GELS vs SILO: Head-to-Head Comparison

This page compares Gelteq Limited (GELS) and Silo Pharma, Inc. (SILO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile